Myeloid Neoplasms and Myeloproliferative Disorders


PEHLİVANOĞLU B., ÖZKAL S.

All Dimensions of Pathology: Volume 2: Clinical Aspects, Springer Nature, ss.415-422, 2026

  • Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1007/978-3-032-23967-9_22
  • Yayınevi: Springer Nature
  • Sayfa Sayıları: ss.415-422
  • Anahtar Kelimeler: Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Essential thrombocythemia (ET), Hematopoietic stem cell disorders, Mastocytosis, Molecular diagnostics, Myelodysplastic neoplasms (MDN), Myelodysplastic/myeloproliferative neoplasms (MDS/MPN), Myeloproliferative neoplasms (MPN), Polycythemia vera (PV), Primary myelofibrosis (PMF)
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Myeloid neoplasms encompass a wide spectrum of clonal hematopoietic stem cell disorders with diverse clinical presentations, molecular mechanisms, and prognostic implications. The purpose of this chapter is to provide an integrated overview, emphasizing how advances in molecular diagnostics have refined classification and improved risk-adapted therapeutic strategies. Acute myeloid leukemia (AML) is characterized by the accumulation of myeloid blasts, resulting in bone marrow failure and high mortality without prompt treatment. Myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are marked by the overproduction of mature myeloid elements and are strongly associated with molecular alterations such as BCR::ABL1 translocation and mutations in JAK2, CALR, and MPL genes. Myelodysplastic neoplasms (MDN) are clonal disorders defined by ineffective hematopoiesis, cytopenias, and a risk of progression to AML. Overlapping features of dysplasia and proliferation define the myelodysplastic/myeloproliferative neoplasms (MDS/MPN), with chronic myelomonocytic leukemia being the most frequent entity. Mastocytosis, typically driven by KIT mutations, represents another distinct subgroup with variable clinical course ranging from indolent to aggressive systemic disease. Together, these entities highlight the biological and clinical heterogeneity of myeloid malignancies, underscoring the importance of integrating morphology, cytogenetics, and molecular testing for accurate diagnosis, prognostication, and treatment planning.